Pharmaceutical ingredient Powder Pramipexole Dihydrochloride Sex Enhancement Raw Medicine Material Steroid Hormone for Parkinson treatment 191217-81-9
Appearance: White Powder
Grade: Medicine Grade
Pramipexole is a dopamine agonist belonging to the same class of drugs as Cabergoline. The primary purpose of this drug is in the treatment of Parkinson's disease. Pramipexole is most commonly found under the brand names Sifrol, Mirapexin and Mirapex, although generics are also available. Mirapex is the most well known brand by Boehringer Ingelheim Pharmaceuticals. Along with treating Parkinson's, Pramipexole is also prescribed for the treatment of restless legs syndrome. The drug has also shown promising signs in the treatment of bipolar depression, although it has never officially held this label.
Pramipexole is a dopamine agonist that directly correlates with the prolactin hormone. As dopamine levels in the body go up, prolactin levels go down. It does this by having a direct effect on the dopamine D3 receptor. Although it also acts on the D2 receptor its affinity for the D3 receptor is seven times greater than any existing dopamine agonist.
The effect of Pramipexole on the D3 receptor has a strong impact on the neurological system, which is why it's used to treat Parkinson's disease and in some cases Alzheimer's disease. Through acting on the D3 receptor, Pramipexole also affects a man's sexual interest and activity. Prolactin is in part directly responsible for a man's refractory period, which refers to the time it takes to recover from sexual activity so that performance can occur again. By lowering prolactin through an increase in dopamine, Pramipexole can directly reduce the refractory period resulting in the ability to perform sexually more frequently.
A white to off white powder
A. Meets the requirement
B. IR: similar to Reference Substance
Loss on drying
Any single impurity ≤0.1%
Purity By HPLC R-isomer
Residue on ignition
Isopropyl alcohol ≤5000ppm
Analyse according to Factory Standard , Conform
General introduction:Pramipexole dihydrochloride is a non-ergoline dopamine agonist indicated for treating early-stage Parkinson's disease (PD) andrestless legs syndrome (RLS). It is also sometimes used off-label as a treatment for cluster headache and to counteract the problems with sexual dysfunction experienced by some users of the selective serotonin reuptake inhibitor (SSRI) antidepressants. Pramipexole has shown robust effects on pilot studies in a placebo-controlled proof of concept study in bipolar disorder. It is also being investigated for the treatment of clinical depression and fibromyalgia.
Parkinson's disease is a neurodegenerative disease affecting the substantia nigra, a component of the basal ganglia. The substantia nigra has a high quantity of dopaminergic neurons, which are nerve cells that release theneurotransmitter known as dopamine. When dopamine is released, it may activate dopamine receptors in the striatum, which is another component of the basal ganglia. When neurons of the substantia nigra deteriorate in Parkinson's disease, the striatum no longer properly receives dopamine signals. As a result, the basal ganglia can no longer regulate body movement effectively and motor function becomes impaired. By acting as an agonist for the D2, D3, and D4 dopamine receptors, pramipexole may directly stimulate the underfunctioning dopamine receptors in the striatum, thereby restoring the dopamine signals needed for proper functioning of the basal ganglia .
Hot steroid powder
Sildenafil citrate (Viagra)
Testosterone Sustanon 250
Crepis base(HuanYang Alkali)
Trenbolone Enanthate (parabolan)
Trenbolone Hexahydrobenzyl Carbonate
Superdrol Powder (methyldrostanolone, Methasterone)
4-chloro-17a-methyl androst-1,4 diene-3-
Methandrostenolone (Dianabol, methandienone)
Tamoxifen Citrate (Nolvadex)
Clomiphene citrate (Clomifene citrate,Clomid)